Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

Phase 3sotagliflozinPositive

AI Analysis

Summary

Lexicon Pharmaceuticals completed enrollment of the pivotal Phase 3 SONATA-HCM study evaluating sotagliflozin for symptomatic non-obstructive and obstructive hypertrophic cardiomyopathy. The study completion represents a milestone in the drug's development program.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Enrollment completed

Importance:6/10

Sentiment:

0.60

Phase 3clinical trialenrollment completehypertrophic cardiomyopathysotagliflozinSONATA-HCM

Related Companies

$LXRX

Read the original article

Published by yahoo_finance on July 27, 2026 12:30 PM

Read Original